HC Wainwright reiterated their buy rating on shares of Ligand Pharmaceuticals (NASDAQ:LGND – Free Report) in a report issued on Thursday, Benzinga reports. The brokerage currently has a $157.00 target price on the biotechnology company’s stock. LGND has been the subject of a number of other reports. Oppenheimer initiated coverage on Ligand Pharmaceuticals in a […]

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a note issued to investors on Friday, Benzinga reports. They currently have a $190.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 57.98% from the company’s current price. […]